BEST Inc.

    BEST Inc.

    NNYSE:BEST
    2.78
    USD
    -0.02
    (-0.71%)
    BEST Inc.
    NYSE:BEST
    (New York Stock Exchange)

    Recent

    price

    2.78

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    TTM
    CNY
    162.39
    278.41
    468.45
    1,067.49
    1,296.58
    538.21
    545.58
    574.86
    389.62
    436.04
    426.97
    Revenue per Share
    -41.27
    -71.83
    -103.2
    -65.57
    -26.22
    -10.39
    -104.96
    13.18
    -73.62
    -42.7
    -36.54
    Basic EPS, GAAP
    -28.83
    -39.1
    -72.51
    -78.67
    -102.33
    -10.39
    -29.96
    -152.4
    -65.09
    -37.17
    -26.01
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    - -
    -426.06
    -723.22
    -793.64
    -794.66
    -801.26
    -916.44
    -877.74
    -951.36
    -1,034.18
    -993.83
    Book Value per Share
    - -
    -438.14
    -729.29
    202.15
    182.09
    185.15
    84.29
    106.01
    33.91
    -11.39
    -18.83
    Tangible Book Value per Share
    19
    19
    19
    19
    19
    19
    19
    20
    20
    19
    20
    Basic Weighted Avg Shares
    3,066
    5,256
    8,844
    19,990
    25,116
    10,481
    10,528
    11,426
    7,744
    8,316
    8,543
    Sales/Revenue/Turnover
    -23.59
    -20.7
    -15.83
    -6.39
    -1.02
    -4.21
    -9.23
    -12.8
    -18.42
    -10.31
    -9
    Operating Margin (%)
    85
    147
    246
    364
    441
    150
    157
    191
    189
    189
    - -
    Depreciation Expense
    -718
    -1,059
    -1,363
    -1,228
    -508
    -202
    -2,026
    262
    -1,463
    -814
    -731
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    -23.43
    -20.16
    -15.42
    -6.14
    -2.02
    -1.93
    -19.24
    2.29
    -18.9
    -9.79
    -8.56
    Profit Margin (%)
    - -
    -1,424
    809
    1,579
    -284
    -881
    -3,267
    992
    -935
    -1,762
    -1,672
    Working Capital
    - -
    - -
    8
    2
    1
    4,751
    3,733
    3,251
    2,770
    1,448
    1,204
    LT Debt
    - -
    -8,027
    -13,508
    4,392
    4,140
    3,915
    1,725
    2,217
    804
    -70
    -231
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    CNY

    •

    in mil. unless spec.
    Sep'23
    Dec'23
    Mar'24
    ST Debt
    1,541
    1,828
    2,075
    LT Borrowings
    964
    585
    426
    LT Finance Leases
    23
    864
    778
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    398
    404
    404
    Market Capitalization
    322
    360
    318

    Working Capital

    CNY

    •

    in mil. unless spec.
    Sep'23
    Dec'23
    Mar'24
    Total Current Assets
    2,396
    3,090
    3,235
    Cash, Cash Equivalents & STI
    519
    462
    295
    Accounts Receivable, Net
    870
    1,078
    751
    Inventories
    10
    8
    8
    Total Current Liabilities
    4,473
    4,852
    4,907
    Payables & Accruals
    2,653
    2,415
    2,545
    ST Debt
    1,541
    1,828
    2,075
    Deferred Revenue
    280
    469
    287

    Growth Rates

    CNY

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    -41.06%
    -108.7%
    Free Cash Flow
    - -
    83.44%
    -45.21%
    Net Income, GAAP
    - -
    4.91%
    -44.35%
    Sales/Revenue/Turnover
    - -
    -14.83%
    7.38%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    CNY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    1,803
    1,931
    2,029
    1,981
    7,744
    2023
    1,715
    2,138
    2,227
    2,236
    8,316
    2024
    1,942
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    CNY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -18.44
    -16.75
    -19.23
    -22.19
    -73.62
    2023
    -12.4
    -7.31
    -8.96
    -12.23
    -42.7
    2024
    -8.01
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    CNY

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

    • prnewswire.com

      CARNIVAL CORPORATION OUTPERFORMS GUIDANCE, DELIVERING BEST EVER REVENUES, NET YIELDS AND NET INCOME

    • prnewswire.com

      TRAVEL + LEISURE BRINGS WORLD'S BEST SUMMIT TO LONDON FOR FIRST INTERNATIONAL EDITION

    • seekingalpha.com

      Opus Genetics: A Resounding Study Success Merits A Higher Valuation

    • seekingalpha.com

      Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript

    • globenewswire.com

      Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

    • gurufocus.com

      BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

    • businesswire.com

      BEST and Luvata Announce Collaboration Agreement for Supply of High-Performance RRP® Superconductors for Magnetic Confinement Fusion

    • globenewswire.com

      Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

    • gurufocus.com

      Bruker Reports Second Quarter 2026 Financial Results

    • gurufocus.com

      FreeCast Announces FreeCast Cities™, a Free Local Streaming Platform Designed for All 210 U.S. Television Markets

    • globenewswire.com

      Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

    • newsfilecorp.com

      OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

    • prnewswire.com

      NEVADA KING GRADUATES TO THE PREMIUM OTCQX BEST MARKET, ENHANCING VISIBILITY FOR U.S. INVESTORS

    • prnewswire.com

      S&T BANK NAMED A FORBES AMERICA'S BEST-IN-STATE BANK FOR 2026

    • prnewswire.com

      IN A SALUTE TO AMERICA'S 250TH BIRTHDAY, SEAWORLD PARKS LAUNCH THEIR BEST OFFER OF THE YEAR WITH THE FOURTH OF JULY SALE

    • prnewswire.com

      IN A SALUTE TO AMERICA'S 250TH BIRTHDAY, BUSCH GARDENS LAUNCHES ITS BEST DEAL OF THE YEAR WITH THE FOURTH OF JULY SALE

    • prnewswire.com

      KIA EARNS FOUR HONORS IN U.S. NEWS & WORLD REPORT'S 2026 "BEST ADVENTURE VEHICLES" AWARDS

    • marketbeat.com

      Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst

    • prnewswire.com

      2027 KIA TELLURIDE NAMED BEST THREE-ROW FAMILY SUV BY THE NORTHWEST AUTOMOTIVE PRESS ASSOCIATION (NWAPA)